Business Information
The group's principal activities are to develop asymmetric products and technology for the life sciences industry. The group has two main lines of products and services - proprietary chiral catalysts and chiral building blocks or client-defined molecules. The products are used in pharmaceuticals, producing fine chemicals other than pharmaceuticals - chiral molecules are used in flavors, fragrances, agrochemicals, animal health, food and feed additives (including vitamins) and nutraceuticals. It also develops and makes client-defined building blocks and drug candidate fragments, mainly in the chiral area, which develops new synthetic routes or optimizes existing ones and produce certain quantities of material for further processing at the clients' needs. The group has license to 13 United States patent applications.
|
|
Name |
Title
|
Email
|
| Francis Giles | Chmn. - Advisory Board | N/A | | Stephen Rocamboli | Non - Exec. Chmn., Sec. | N/A | | Brian Lenz | Interim CEO, CFO, Treasurer | N/A | | Edward Bradley | Chief Scientific Officer | N/A | | Lawrence Akinsanmi | VP - Clinical Operations, Regulatory Affairs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | N/A | (8,271) | | 2005 | 3,805 | (12,835) | | 2004 | 1,485 | (4,024)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
